Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 12/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058402 | 0.86 | SCN9A (0.49) | HCRTR2HCRTR1CDK4CCND1SCN9A | |
| SCHEMBL1398880 | 0.86 | TSHR (0.54) | HCRTR2HCRTR1 | |
| SCHEMBL3058144 | 0.86 | CDK4 (0.46) | HCRTR2HCRTR1GRM5CDK4CCND1 | |
| SCHEMBL3048571 | 0.85 | RORB (0.50) | HCRTR2HCRTR1MAOAMAOBPDK2 | |
| SCHEMBL3063297 | 0.82 | HCRTR2 (0.50) | HCRTR2HCRTR1GRM5CDK4CCND1 | |
| SCHEMBL3065362 | 0.81 | MAOB (0.43) | CDK4CCND1MAOBPDE4BPDK2 | |
| SCHEMBL1398915 | 0.81 | HCRTR1 (0.47) | HCRTR2HCRTR1PDK2ALOX5APFEN1 | |
| SCHEMBL3058143 | 0.79 | HCRTR1 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL4740969 | 0.79 | PDK2 (0.51) | HCRTR2HCRTR1SCN9APDK2 | |
| SCHEMBL3415999 | 0.77 | HCRTR2 (0.48) | HCRTR2HCRTR1GRM5CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR2 1/4885HCRTR1 2/4885GRM5 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.